Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

LATISSE

×

Overview

What is LATISSE?

LATISSE

Z

R

R

R

S

E

S

N

Bimatoprost is a powder, which is very soluble in ethyl alcohol and methyl alcohol and slightly soluble in water. is a clear, isotonic, colorless, sterile ophthalmic solution with an osmolality of approximately 290 mOsmol/kg.

Contains: Active:

Preservative:

Inactives:



What does LATISSE look like?



What are the available doses of LATISSE?

Bimatoprost ophthalmic solution 0.3 mg/mL. ()

What should I talk to my health care provider before I take LATISSE?

How should I use LATISSE?

LATISSE

Ensure the face is clean, makeup and contact lenses are removed. Once nightly, place one drop of (bimatoprost ophthalmic solution) 0.03% on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. The upper lid margin in the area of lash growth should feel lightly moist without runoff. Blot any excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth. Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator.

Do not reuse applicators and do not use any other brush/applicator to apply .

Do not apply to the lower eyelash line .

Additional applications of will not increase the growth of eyelashes.

Upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level.


What interacts with LATISSE?

Sorry No Records found


What are the warnings of LATISSE?

Sorry No Records found


What are the precautions of LATISSE?

Sorry No Records found


What are the side effects of LATISSE?

Sorry No records found


What should I look out for while using LATISSE?

LATISSE

see Adverse Reactions ()


What might happen if I take too much LATISSE?

Sorry No Records found


How should I store and handle LATISSE?

Pre-filled dual chamber syringe:Store below 30°C [86°F]. Do not freeze. Protect the syringe from light by storing in the original package until time of use. Vial:Store at 25°C (77°F), excursions permitted between 15°C and 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Pre-filled dual chamber syringe:Store below 30°C [86°F]. Do not freeze. Protect the syringe from light by storing in the original package until time of use. Vial:Store at 25°C (77°F), excursions permitted between 15°C and 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Pre-filled dual chamber syringe:Store below 30°C [86°F]. Do not freeze. Protect the syringe from light by storing in the original package until time of use. Vial:Store at 25°C (77°F), excursions permitted between 15°C and 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Pre-filled dual chamber syringe:Store below 30°C [86°F]. Do not freeze. Protect the syringe from light by storing in the original package until time of use. Vial:Store at 25°C (77°F), excursions permitted between 15°C and 30°C (59°F to 86°F) [see USP Controlled Room Temperature].LATISSE3 mL in a 5 mL bottle with 70 applicators NDC 0023-3616-70 5 mL in a 5 mL bottle with 140 applicators NDC 0023-3616-05 LATISSE3 mL in a 5 mL bottle with 70 applicators NDC 0023-3616-70 5 mL in a 5 mL bottle with 140 applicators NDC 0023-3616-05 LATISSE3 mL in a 5 mL bottle with 70 applicators NDC 0023-3616-70 5 mL in a 5 mL bottle with 140 applicators NDC 0023-3616-05


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Bimatoprost is a structural prostaglandin analog. Although the precise mechanism of action is unknown the growth of eyelashes is believed to occur by increasing the percent of hairs in, and the duration of the anagen or growth phase.

Non-Clinical Toxicology
LATISSE

see Adverse Reactions ()

Ranitidine has been reported to affect the bioavailability of other drugs through several different mechanisms such as competition for renal tubular secretion, alteration of gastric pH, and inhibition of cytochrome P450 enzymes.









Ranitidine may alter the absorption of drugs in which gastric pH is an important determinant of bioavailability. This can result in either an increase in absorption (e.g., triazolam, midazolam, glipizide) or a decrease in absorption (e.g., ketoconazole, atazanavir, delavirdine, gefitinib). Appropriate clinical monitoring is recommended.





























Bimatoprost ophthalmic solution ( ) lowers intraocular pressure (IOP) when instilled directly to the eye in patients with elevated IOP. In clinical trials, in patients with or without elevated IOP, lowered IOP, however, the magnitude of the reduction was not cause for clinical concern.

In ocular hypertension studies with , it has been shown that exposure of the eye to more than one dose of bimatoprost daily may decrease the intraocular pressure lowering effect. In patients using or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including for IOP reduction should only use after consulting with their physician and should be monitored for changes to their intraocular pressure .

The following adverse reactions are described elsewhere in the labeling:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).